Aceragen (ACGN) 10-Q 12 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Jul. 15, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'IDRA	'
Entity Registrant Name	'IDERA PHARMACEUTICALS, INC.	'
Entity Central Index Key	'0000861838	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	83,767,193

Condensed_Balance_Sheets_Unaud

Condensed Balance Sheets (Unaudited) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$54,886	$26,278
Short-term investments	8,844	3,125
Prepaid expenses and other current assets	836	874
Total current assets	64,566	30,277
Long-term investments	1,004	6,189
Property and equipment, net	686	90
Restricted cash	311	311
Total assets	66,567	36,867
Current liabilities:	'	'
Accounts payable	2,026	904
Accrued expenses	4,221	3,506
Total current liabilities	6,247	4,410
Other liabilities	59	5
Total liabilities	6,306	4,415
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Preferred stock, $0.01 par value, Authorized - 5,000 shares	0	0
Common stock, $0.001 par value, Authorized - 280,000 shares; Issued and outstanding - 83,758 and 66,252 shares at June 30, 2014 and December 31, 2013, respectively	84	66
Additional paid-in capital	484,799	434,285
Accumulated deficit	-430,153	-412,884
Accumulated other comprehensive gain (loss)	3	-7
Total stockholders' equity	60,261	32,452
Total liabilities and stockholders' equity	66,567	36,867
Series E preferred stock [Member]	'	'
Stockholders' equity:	'	'
Preferred stock, $0.01 par value	5,528	5,528
Series D preferred stock [Member]	'	'
Stockholders' equity:	'	'
Preferred stock, $0.01 par value	'	5,464
Series A preferred stock [Member]	'	'
Stockholders' equity:	'	'
Preferred stock, $0.01 par value	$0	$0

Condensed_Balance_Sheets_Unaud1

Condensed Balance Sheets (Unaudited) (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value	0.001	$0.00
Common stock, shares authorized	280,000,000	280,000,000
Common stock, shares issued	83,758,000	66,252,000
Common stock, shares outstanding	83,758,000	66,252,000
Series E preferred stock [Member]	'	'
Preferred stock, par value	0.01	$0.01
Preferred stock, shares designated	424,000	424,000
Preferred stock, shares issued	424,000	424,000
Preferred stock, shares outstanding	424,000	424,000
Series D preferred stock [Member]	'	'
Preferred stock, par value	'	$0.01
Preferred stock, shares designated	0	1,124,000
Preferred stock, shares issued	0	1,124,000
Preferred stock, shares outstanding	0	1,124,000
Series A preferred stock [Member]	'	'
Preferred stock, par value	0.01	$0.01
Preferred stock, shares designated	1,500,000	1,500,000
Preferred stock, shares issued	1,000	1,000
Preferred stock, shares outstanding	1,000	1,000

Condensed_Statements_of_Operat

Condensed Statements of Operations and Comprehensive Loss (Unaudited) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Statement Of Income And Comprehensive Income [Abstract]	'	'	'	'
Alliance revenue	$38	$29	$41	$36
Operating expenses:	'	'	'	'
Research and development	5,637	1,997	12,570	4,325
General and administrative	2,730	1,599	4,773	3,126
Total operating expenses	8,367	3,596	17,343	7,451
Loss from operations	-8,329	-3,567	-17,302	-7,415
Other income (expense):	'	'	'	'
Investment income, net	16	2	31	4
Foreign currency exchange gain (loss)	5	-26	2	13
Net loss	-8,308	-3,591	-17,269	-7,398
Loss on extinguishment of convertible preferred stock and preferred stock dividends	118	2,030	303	2,309
Net loss applicable to common stockholders	-8,426	-5,621	-17,572	-9,707
Basic and diluted net loss per common share applicable to common stockholders (Note 13)	($0.10)	($0.15)	($0.22)	($0.30)
Shares used in computing basic and diluted net loss per common share applicable to common stockholders	82,961	38,048	79,509	32,875
Net loss	-8,308	-3,591	-17,269	-7,398
Other comprehensive (loss) gain:	'	'	'	'
Unrealized (loss) gain on available-for-sale securities	-1	'	10	'
Comprehensive loss	($8,309)	($3,591)	($17,259)	($7,398)

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Cash Flows from Operating Activities:	'	'
Net loss	($17,269)	($7,398)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Stock-based compensation	1,320	518
Depreciation and amortization expense	78	75
Amortization of investment premiums	96	'
Issuance of common stock for services rendered	36	9
Other	-3	8
Changes in operating assets and liabilities:	'	'
Prepaid expenses and other current assets	38	-4
Accounts payable, accrued expenses, and other liabilities	1,947	-1,214
Net cash used in operating activities	-13,757	-8,006
Cash Flows from Investing Activities:	'	'
Purchases of available-for-sale securities	-2,619	'
Maturities of available-for-sale securities	2,000	'
Purchases of property and equipment	-533	-1
Net cash used in investing activities	-1,152	-1
Cash Flows from Financing Activities:	'	'
Proceeds from equity financings	37,202	14,721
Dividends paid	-463	-509
Proceeds from exercise of common stock warrants and options and employee stock purchases	6,780	2
Payments on capital lease	-2	-2
Net cash provided by financing activities	43,517	14,212
Net increase in cash and cash equivalents	28,608	6,205
Cash and cash equivalents, beginning of period	26,278	10,096
Cash and cash equivalents, end of period	$54,886	$16,301

Organization

Organization	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Organization	'
	(1) Organization
	Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) is a clinical stage biotechnology company advancing drug candidates for the treatment of certain genetically defined forms of B-cell lymphoma and for the treatment of orphan autoimmune diseases. These drug candidates are designed to inhibit over-activation of specific Toll-like receptors (“TLRs”). In addition to Idera’s TLR program, the Company has initiated a research program to develop its gene silencing oligonucleotides (“GSOs”) to inhibit the production of disease-associated proteins by targeting RNA.
	The Company’s lead drug candidate in its TLR program is IMO-8400, an antagonist of TLR7, TLR8, and TLR9. A TLR antagonist is a compound that blocks activation of an immune response through the targeted TLR. IMO-8400 is in clinical development for the treatment of certain genetically defined forms of B-cell lymphoma and for the treatment of selected orphan autoimmune diseases. The Company has completed a Phase 1 trial of IMO-8400 in healthy subjects and a Phase 2 randomized, placebo-controlled trial in patients with moderate to severe plaque psoriasis. In both trials, IMO-8400 has been well tolerated and, in the Phase 2 trial, has shown clinical proof of concept. Currently IMO-8400 is being evaluated in a Phase 1/2 trial in patients with Waldenström’s macroglobulinemia and in a Phase 1/2 trial in patients with diffuse large B-cell lymphoma, or DLBCL, who harbor the MYD88 L265P oncogenic mutation. The Company is also advancing, a second novel antagonist of TLR7, TLR8, and TLR9, IMO-9200, as a drug candidate for potential use in selected autoimmune disease indications. The Company has completed preclinical studies of IMO-9200 to support initiation of clinical development.
	Idera’s business strategy is to develop IMO-8400, IMO-9200, and other TLR antagonist drug candidates for the treatment of certain genetically defined forms of B-cell lymphoma and for the treatment of orphan autoimmune diseases with unmet medical needs. In addition, the Company may seek to enter into collaborative alliances with pharmaceutical companies to advance its TLR antagonist candidates in broader autoimmune disease indications, such as psoriasis, lupus, and arthritis.
	At June 30, 2014, the Company had an accumulated deficit of $430,153,000. The Company expects to incur substantial operating losses in future periods. The Company does not expect to generate significant product revenue, sales-based milestones or royalties until the Company successfully completes development and obtains marketing approval for drug candidates, either alone or in collaborations with third parties, which the Company expects will take a number of years. In order to commercialize its drug candidates, the Company needs to complete clinical development and comply with comprehensive regulatory requirements.
	The Company is subject to a number of risks and uncertainties similar to those of other companies of the same size within the biotechnology industry, such as uncertainty of clinical trial outcomes, uncertainty of additional funding, and history of operating losses.

New_Accounting_Pronouncements_

New Accounting Pronouncements - Recently Issued	6 Months Ended
	Jun. 30, 2014
Accounting Changes And Error Corrections [Abstract]	'
New Accounting Pronouncements - Recently Issued	'
	(2) New Accounting Pronouncements - Recently Issued
	In April 2014, the FASB issued ASU No. 2014-08, which amends guidance for reporting discontinued operations and disposals of components of an entity. The amended guidance requires that a disposal representing a strategic shift that has (or will have) a major effect on an entity’s operations and financial results or a business activity classified as held for sale should be reported as discontinued operations. The amendments also expand the disclosure requirements for discontinued operations and add new disclosure requirements for individually significant dispositions that do not qualify as discontinued operations. This guidance is effective prospectively for fiscal years beginning after December 15, 2014 (early adoption is permitted only for disposals that have not been previously reported). The Company does not expect the adoption of this guidance to have a material effect on its consolidated financial statements.
	In May 2014, the FASB issued ASU No. 2014-09, which amends the guidance for accounting for revenue from contracts with customers. This ASU supersedes the revenue recognition requirements in Accounting Standards Codification Topic 605, Revenue Recognition, and creates a new Topic 606, Revenue from Contracts with Customers. This guidance is effective for fiscal years beginning after December 15, 2016, with early adoption not permitted. Two adoption methods are permitted: retrospectively to all prior reporting periods presented, with certain practical expedients permitted; or retrospectively with the cumulative effect of initially adopting the ASU recognized at the date of initial application. The Company has not yet determined which adoption method it will utilize or the effect that the adoption of this guidance will have on its consolidated financial statements.

Unaudited_Interim_Financial_St

Unaudited Interim Financial Statements	6 Months Ended
	Jun. 30, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Unaudited Interim Financial Statements	'
	(3) Unaudited Interim Financial Statements
	The accompanying unaudited financial statements included herein have been prepared by the Company in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments, consisting of normal recurring adjustments, and disclosures considered necessary for a fair presentation of interim period results have been included. Interim results for the six months ended June 30, 2014 are not necessarily indicative of results that may be expected for the year ended December 31, 2014. For further information, refer to the financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013, which was filed with the SEC on March 13, 2014.

Financial_Instruments

Financial Instruments	6 Months Ended
	Jun. 30, 2014
Investments All Other Investments [Abstract]	'
Financial Instruments	'
	(4) Financial Instruments
	The fair value of the Company’s financial instruments is determined and disclosed in accordance with the three-tier fair value hierarchy specified in Note 6, “Fair Value of Assets and Liabilities.” The Company is required to disclose the estimated fair values of its financial instruments. The Company’s financial instruments consist of cash, cash equivalents, available-for-sale investments and receivables. The estimated fair values of these financial instruments approximate their carrying values as of June 30, 2014 and December 31, 2013. As of June 30, 2014 and December 31, 2013, the Company did not have any derivatives, hedging instruments or other similar financial instruments except for the Company’s Series E convertible preferred stock (the “Series E preferred stock”), the embedded features of which are discussed in Note 9(g) to the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

Cash_and_Cash_Equivalents

Cash and Cash Equivalents	6 Months Ended
	Jun. 30, 2014
Cash And Cash Equivalents [Abstract]	'
Cash and Cash Equivalents	'
	(5) Cash and Cash Equivalents
	The Company considers all highly liquid investments with maturities of 90 days or less when purchased to be cash equivalents. Cash and cash equivalents at June 30, 2014 and December 31, 2013 consisted of cash and money market funds.

Fair_Value_of_Assets_and_Liabi

Fair Value of Assets and Liabilities	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Assets and Liabilities	'
	(6) Fair Value of Assets and Liabilities
	The Company measures fair value at the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date using assumptions that market participants would use in pricing the asset or liability (the “inputs”) into a three-tier fair value hierarchy. This fair value hierarchy gives the highest priority (Level 1) to quoted prices in active markets for identical assets or liabilities and the lowest priority (Level 3) to unobservable inputs in which little or no market data exists, requiring companies to develop their own assumptions. Observable inputs that do not meet the criteria of Level 1, and include quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets and liabilities in markets that are not active, are categorized as Level 2. Level 3 inputs are those that reflect the Company’s estimates about the assumptions market participants would use in pricing the asset or liability, based on the best information available in the circumstances. Valuation techniques for assets and liabilities measured using Level 3 inputs may include unobservable inputs such as projections, estimates and management’s interpretation of current market data. These unobservable Level 3 inputs are only utilized to the extent that observable inputs are not available or cost-effective to obtain. The Company applies Accounting Standards Update (“ASU”) No. 2011-04, “Fair Value Measurement (Topic 820),” in its fair value measurements and disclosures.
	The table below presents the assets and liabilities measured and recorded in the financial statements at fair value on a recurring basis at June 30, 2014 and December 31, 2013 categorized by the level of inputs used in the valuation of each asset and liability.
	(In thousands)	Total		Quoted Prices		Significant		Significant
				in Active		Other		Unobservable
				Markets		Observable		Inputs
				for Identical		Inputs		(Level 3)
				Assets or		(Level 2)
				Liabilities
				(Level 1)
	June 30, 2014
	Assets
	Money market funds	$	54,814	$	54,814	$	—	$	—
	Short-term investments – commercial paper		998		—		998		—
	Short-term investments – corporate bonds		7,846		—		7,846		—
	Long-term investments – corporate bonds		1,004		—		1,004		—
	Total Assets	$	64,662	$	54,814	$	9,848	$	—
	December 31, 2013
	Assets
	Money market funds	$	25,201	$	25,201	$	—	$	—
	Short-term investments – commercial paper		1,997		—		1,997		—
	Short-term investments – corporate bonds		1,128		—		1,128		—
	Long-term investments – corporate bonds		6,189		—		6,189		—
	Total Assets	$	34,515	$	25,201	$	9,314	$	—
	The Level 1 assets consist of money market funds, which are actively traded daily. The Level 2 assets consist of corporate bond and commercial paper investments whose fair value may not represent actual transactions of identical securities. The fair value of corporate bonds is generally determined from quoted market prices received from pricing services based upon quoted prices from active markets and/or other significant observable market transactions at fair value. The fair value of commercial paper is generally determined based on the relationship between the investment’s discount rate and the discount rates of the same issuer’s commercial paper available in the market which may not be actively traded daily. Since these fair values may not be based upon actual transactions of identical securities, they are classified as Level 2. Since any investments are classified as available-for-sale securities, any unrealized gains or losses are recorded in accumulated other comprehensive gain (loss) or within stockholders’ equity on the balance sheets. The Company did not elect to measure any other financial assets or liabilities at fair value at June 30, 2014 or December 31, 2013.

Investments

Investments	6 Months Ended
	Jun. 30, 2014
Investments Debt And Equity Securities [Abstract]	'
Investments	'
	(7) Investments
	The Company’s available-for-sale investments at fair value consisted of the following at June 30, 2014 and December 31, 2013:
		June 30, 2014
		Cost		Gross			Gross		Estimated
				Unrealized			Unrealized		Fair Value
				(Losses)			Gains
		(In thousands)
	Commercial paper due in one year or less	$	998	$	—		$	—	$	998
	Corporate bonds due in one year or less		7,842		—			4		7,846
	Total short-term investments		8,840		—			4		8,844
	Total long-term investments		1,005		(1	)		—		1,004
	Total investments	$	9,845	$	(1	)	$	4	$	9,848
		December 31, 2013
		Cost		Gross			Gross		Estimated
				Unrealized			Unrealized		Fair Value
				(Losses)			Gains
		(In thousands)
	Commercial paper due in one year or less	$	1,997	$	—		$	—	$	1,997
	Corporate bonds due in one year or less		1,128		—			—		1,128
	Total short-term investments		3,125		—			—		3,125
	Corporate bonds due in one year or more		6,196		(7	)		—		6,189
	Total long-term investments		6,196		(7	)		—		6,189
	Total investments	$	9,321	$	(7	)	$	—	$	9,314
	The Company had no realized gains or losses from available-for-sale securities in the six months ended June 30, 2014 and 2013. There were no losses or other-than-temporary declines in value included in “Investment income, net” on the Company’s condensed statements of operations and comprehensive loss for any securities for the three and six months ended June 30, 2014 and 2013. The Company had no auction rate securities as of June 30, 2014 and December 31, 2013. See Note 4, “Financial Instruments,” and Note 6, “Fair Value of Assets and Liabilities” for additional information related to the Company’s investments.

Property_and_Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2014
Property Plant And Equipment [Abstract]	'
Property and Equipment	'
	(8) Property and Equipment
	At June 30, 2014 and December 31, 2013, net property and equipment at cost consisted of the following:
	(In thousands)	June 30,		December 31,
		2014		2013
	Leasehold improvements	$	525	$	525
	Laboratory equipment and other		3,238		2,854
	Total property and equipment, at cost		3,763		3,379
	Less: accumulated depreciation		3,077		3,289
	Property and equipment, net	$	686	$	90
	Depreciation and amortization expense was approximately $47,000 and $33,000 in the three months ended June 30, 2014 and 2013, respectively, and approximately $78,000 and $75,000 in the six months ended June 30, 2014 and 2013, respectively.

Restricted_Cash

Restricted Cash	6 Months Ended
	Jun. 30, 2014
Cash And Cash Equivalents [Abstract]	'
Restricted Cash	'
	(9) Restricted Cash
	As part of the Company’s lease arrangement for its office and laboratory facility, the Company is required to restrict cash held in a certificate of deposit securing a line of credit for the lessor. As of June 30, 2014 and December 31, 2013, the restricted cash amounted to $311,000 held in certificates of deposit securing a line of credit for the lessor.

Collaborations

Collaborations	6 Months Ended
	Jun. 30, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Collaborations	'
	(10) Collaborations
	(a) Collaboration with Abbott Molecular Inc.
	In May 2014, the Company entered into a collaboration with Abbott Molecular, Inc. (“Abbott Molecular”) for the development of a companion diagnostic that can be used to identify patients with the MYD88 L265P oncogenic mutation. Under the agreement, Abbott Molecular has agreed to develop the companion diagnostic to comply with the requirements of the U.S. Food and Drug Administration (“FDA”) Center for Devices and Radiological Health. The Company expects to pay approximately $6,700,000 in external development expenses over five years under the agreement to develop an assay as the prototype of the companion diagnostic, to validate the prototype during a Phase 2 clinical trial of IMO-8400, and to complete FDA regulatory requirements and launch activities of the resultant final version of the companion diagnostic. Such expenses are subject to increase if Abbott Molecular incurs additional expenses in order to meet unexpected material requirements or obligations not included in the agreement or if the Company is required to conduct additional or different clinical trials which result in Abbott Molecular incurring additional costs. The Company will not receive any revenues from future sales, if any, of the companion diagnostic. The Company expects to use the prototype companion diagnostic developed by Abbott Molecular in its ongoing Phase 1/2 clinical trial of IMO-8400 in patients with DLBCL beginning in the fourth quarter of 2014 and in future clinical trials of IMO-8400. The Company incurred $1,300,000 in expenses under the Abbott Molecular agreement through June 30, 2014.
	(b) Amendment to Exclusive License and Research Collaboration Agreement with Merck Sharp & Dohme Corp.
	In April 2014, the Company entered into an amendment to its exclusive license and research collaboration agreement with Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc. (“Merck & Co.”)). Under the license and research collaboration agreement, which the Company entered into with Merck & Co. in December 2006, the Company had granted Merck & Co. worldwide exclusive rights to its TLR7, TLR8, and TLR9 agonists for use in combination with Merck & Co.’s therapeutic and prophylactic vaccines under development in the fields of cancer, infectious diseases, and Alzheimer’s disease. As a result of this amendment, Merck & Co.’s rights under the license and research collaboration agreement have been limited to specified TLR7, TLR8, and TLR9 agonists that Merck & Co. selected in January 2012, and the Company regained the rights to pursue its other independently discovered TLR7, TLR8, and TLR9 agonists for use as vaccine adjuvants in the fields of cancer, infectious diseases and Alzheimer’s disease so that it now has the right to pursue its TLR7, TLR8, and TLR9 agonists for use as vaccine adjuvants in all fields. Merck & Co.’s obligations under the agreement to pay the Company milestone payments and royalties continue in effect with respect to the specified TLR7, TLR8, and TLR9 agonists. However, in connection with this amendment, the Company agreed that, to the extent that the Company licenses to third parties any TLR7, TLR8, and TLR9 agonists for use as vaccine adjuvants in the fields of cancer, infectious diseases and Alzheimer’s disease and receives income under such licenses, Merck & Co. may credit against any milestone payments and royalties it owes to the Company an amount equal to 15% of the license income received by the Company under the third-party licenses, up to a maximum of $60.0 million in credits.

Comprehensive_Income_Loss

Comprehensive Income (Loss)	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Comprehensive Income (Loss)	'
	(11) Comprehensive Income (Loss)
	Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss for the six months ended June 30, 2014 and 2013 is comprised of reported net loss and any change in net unrealized gains and losses on investments during each period, which is included in accumulated other comprehensive gain (loss) on the accompanying balance sheets. The Company applies ASU No. 2011-05, “Comprehensive Income” by presenting the components of net income and other comprehensive income as one continuous statement.
	The following table includes the changes in the accumulated balance of the component of other comprehensive gain (loss) for the six months ended June 30, 2014:
	(In thousands)	Six Months
		ended June 30,
		2014
	Accumulated unrealized loss on available-for-sale securities at beginning of period	$	(7	)
	Change during the period		10
	Accumulated unrealized gain on available-for-sale securities at end of period	$	3
	There was no accumulated unrealized gain or loss on available-for-sale securities during the six months ended June 30, 2013.

StockBased_Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock-Based Compensation	'
	(12) Stock-Based Compensation
	The Company recognizes all share-based payments to employees and directors as expense in the statements of operations and comprehensive loss based on their fair values. The Company records compensation expense over an award’s requisite service period, or vesting period, based on the award’s fair value at the date of grant. The Company’s policy is to charge the fair value of stock options as an expense, adjusted for forfeitures, on a straight-line basis over the vesting period, which is generally four years for employees and three years for directors.
	The Company recorded charges of $785,000 and $265,000 in its statements of operations and comprehensive loss for the three months ended June 30, 2014 and 2013, respectively, and $1,320,000 and $518,000 in its statements of operations and comprehensive loss for the six months ended June 30, 2014 and 2013, respectively, for stock-based compensation expense attributable to share-based payments made to employees and directors. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The following assumptions apply to the options to purchase 2,116,000 and 1,720,083 shares of common stock granted to employees and directors during the six months ended June 30, 2014 and 2013, respectively:
		Six Months Ended June 30,
		2014			2013
	Average risk free interest rate		1.6	%		0.9	%
	Expected dividend yield		—			—
	Expected lives (years)		4.8			5
	Expected volatility		83	%		61	%
	Weighted average grant date fair value of options granted during the period (per share)	$	2.61		$	0.36
	Weighted average exercise price of options granted during the period (per share)	$	4.01		$	0.69
	The expected lives and the expected volatility of the options granted during the six months ended June 30, 2014 and 2013 are based on historical experience. All options granted during the six months ended June 30, 2014 and 2013 were granted at exercise prices equal to the fair market value of the common stock on the dates of grant.

Net_Loss_per_Common_Share_Appl

Net Loss per Common Share Applicable to Common Stockholders	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Net Loss per Common Share Applicable to Common Stockholders	'
	(13) Net Loss per Common Share Applicable to Common Stockholders
	For the three and six months ended June 30, 2014 and 2013, basic and diluted net loss per common share applicable to common stockholders is computed using the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share applicable to common stockholders is the same as basic net loss per common share applicable to common stockholders as the effects of the Company’s potential common stock equivalents are antidilutive. Total antidilutive securities were 80,016,676 and 85,807,964 for the six months ended June 30, 2014 and 2013, respectively, and consist of stock options, preferred stock and warrants.
	For the three months ended June 30, 2014, net loss per common share applicable to common stockholders reflects $118,000 in dividends accrued on shares of the Series E preferred stock. For the six months ended June 30, 2014, net loss per common share applicable to common stockholders reflects $303,000 in dividends accrued on shares of the Company’s Series D convertible preferred stock (“Series D preferred stock”) and the Series E preferred stock. As discussed in Note 15, “Related Party Transactions,” the Series D preferred stock was converted to common stock on February 6, 2014. For the three and six months ended June 30, 2013, net loss per common share applicable to common stockholders reflects $1,750,000 related to the loss on extinguishment of the Series D preferred stock and the Series E preferred stock that the Company issued in November 2011 and November 2012, respectively, that has been charged to net loss applicable to common stockholders as a preferred stock dividend, and $280,000 and $559,000, respectively, in dividends payable on shares of Series D preferred stock and Series E preferred stock. The $1,750,000 loss on extinguishment of the Series D preferred stock and the Series E preferred stock in the three and six months ended June 30, 2013 was recorded following the irrevocable waiver by the holder of the Series D preferred stock of the Series D preferred stock redemption rights and liquidation preferences and by the holders of the Series E preferred stock of the Series E preferred stock liquidation preferences, which irrevocable waivers became effective when the Company completed its follow-on underwritten public offering on May 7, 2013. The Company determined that the irrevocable waivers represented changes to the fundamental terms of both the Series D preferred stock and the Series E preferred stock and therefore accounted for them as an extinguishment of the Series D preferred stock and the Series E preferred stock.

Common_Stock_Warrant_and_Optio

Common Stock Warrant and Option Exercises and Employee Stock Purchases	6 Months Ended
	Jun. 30, 2014
Text Block [Abstract]	'
Common Stock Warrant and Option Exercises and Employee Stock Purchases	'
	(14) Common Stock Warrant and Option Exercises and Employee Stock Purchases
	During the six months ended June 30, 2014, the Company issued 3,364,033 shares of common stock in connection with warrant and stock option exercises and purchases under the Company’s 1995 Employee Stock Purchase Plan (the “ESPP”) resulting in total proceeds to the Company of $6,780,000.
	During the six months ended June 30, 2013, the Company issued 3,574 shares of common stock in connection with employee stock purchases under the ESPP, which resulted in total proceeds to the Company of $2,000. During this period, there were no warrant or option exercises.

Related_Party_Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	(15) Related Party Transactions
	February 6, 2014 Conversion of Series D Preferred Stock
	On January 10, 2014, the Company notified Pillar Pharmaceuticals I, L.P. (“Pillar I”), an investment partnership managed by one of the Company’s directors and significant stockholders and the holder of all 1,124,260 shares of the Company’s issued and outstanding Series D preferred stock, of its intention to redeem the Series D preferred stock on February 10, 2014 in accordance with the terms of the Certificate of Designations, Preferences and Rights of Series D Preferred Stock (the “Series D Certificate of Designations”). Following this notice, Pillar I had the right to convert its Series D preferred stock into shares of the Company’s common stock at any time prior to the close of business on February 9, 2014. On February 6, 2014, Pillar I converted such shares into 6,266,175 shares of the Company’s common stock in accordance with the terms of the Series D Certificate of Designations. As a result of the conversion, no shares of the Company’s Series D preferred stock remain outstanding.
	On March 28, 2014, the Company filed a Certificate of Elimination of Number of Shares of Preferred Stock Designated as Series D Convertible Preferred Stock with the State of Delaware Secretary of State which eliminated the designation of the shares of Series D preferred stock.
	Director Stock Purchases
	The Company issued 8,546 and 18,617 shares of common stock in lieu of director board and committee fees of approximately $36,000 and $9,000 pursuant to the Company’s director compensation program during the six months ended June 30, 2014 and 2013, respectively.

Financing

Financing	6 Months Ended
	Jun. 30, 2014
Text Block [Abstract]	'
Financing	'
	(16) Financing
	February 10, 2014 Follow-on Underwritten Public Offering
	On February 10, 2014, the Company closed a follow-on underwritten public offering, in which it sold 7,867,438 shares of common stock at a price to the public of $4.00 per share and pre-funded warrants to purchase up to 2,158,750 shares of common stock at a price to the public of $3.99 per share for aggregate gross proceeds of $40.1 million. The pre-funded warrants have an exercise price of $0.01 per share and will expire if not exercised by February 10, 2021. The estimated net proceeds to the Company from the offering, after deducting underwriters’ discounts and commissions and other offering costs and expenses and excluding the proceeds of the exercise of the warrants, if any, were approximately $37.2 million.
	May 7, 2013 Follow-on Underwritten Public Offering
	On May 7, 2013, the Company closed a follow-on underwritten public offering, in which it sold 17,500,000 shares of common stock, together with matching warrants to purchase up to 17,500,000 shares of common stock, and pre-funded warrants to purchase up to 15,816,327 shares of common stock, together with matching warrants to purchase up to 15,816,327 shares of common stock, for aggregate gross proceeds of $16.5 million as follows:
		Combined Price		Common		Pre-funded		Matching
		to the Public		Stock		Warrants		Warrants
		(per share of
		common
		stock)
	Common stock and matching warrants sold (shares)	$	0.5		17,500,000		—		17,500,000
	Pre-funded warrants & matching warrants sold (shares)	$	0.49		—		15,816,327		15,816,327
	Total (shares)				17,500,000		15,816,327		33,316,327
	Warrant exercise price (per share)		—		—	$	0.01	$	0.47
	Term of warrant (years)		—		—		7		5
	The net proceeds to the Company from the offering, after deducting underwriters’ discounts and commissions and offering costs and expenses and excluding the proceeds of the future exercise of the warrants, if any, were approximately $14.5 million.
	The warrants and the pre-funded warrants each provide that, after the second anniversary of the date of issuance, the Company may redeem the warrants for $0.01 per share of common stock issuable on exercise of the warrants following 30 days’ prior written notice to the holder if the closing price of the common stock for 20 or more trading days in a period of 30 consecutive trading days is greater than or equal to $2.80.

Subsequent_Events

Subsequent Events	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	(17) Subsequent Events
	The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure.

New_Accounting_Pronouncements_1

New Accounting Pronouncements - Recently Issued (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Changes And Error Corrections [Abstract]	'
New Accounting Pronouncements - Recently Issued	'
	In April 2014, the FASB issued ASU No. 2014-08, which amends guidance for reporting discontinued operations and disposals of components of an entity. The amended guidance requires that a disposal representing a strategic shift that has (or will have) a major effect on an entity’s operations and financial results or a business activity classified as held for sale should be reported as discontinued operations. The amendments also expand the disclosure requirements for discontinued operations and add new disclosure requirements for individually significant dispositions that do not qualify as discontinued operations. This guidance is effective prospectively for fiscal years beginning after December 15, 2014 (early adoption is permitted only for disposals that have not been previously reported). The Company does not expect the adoption of this guidance to have a material effect on its consolidated financial statements.
	In May 2014, the FASB issued ASU No. 2014-09, which amends the guidance for accounting for revenue from contracts with customers. This ASU supersedes the revenue recognition requirements in Accounting Standards Codification Topic 605, Revenue Recognition, and creates a new Topic 606, Revenue from Contracts with Customers. This guidance is effective for fiscal years beginning after December 15, 2016, with early adoption not permitted. Two adoption methods are permitted: retrospectively to all prior reporting periods presented, with certain practical expedients permitted; or retrospectively with the cumulative effect of initially adopting the ASU recognized at the date of initial application. The Company has not yet determined which adoption method it will utilize or the effect that the adoption of this guidance will have on its consolidated financial statements.

Fair_Value_of_Assets_and_Liabi1

Fair Value of Assets and Liabilities (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Assets and Liabilities Measured at Fair Value on a Recurring Basis	'
	The table below presents the assets and liabilities measured and recorded in the financial statements at fair value on a recurring basis at June 30, 2014 and December 31, 2013 categorized by the level of inputs used in the valuation of each asset and liability.
	(In thousands)	Total		Quoted Prices		Significant		Significant
				in Active		Other		Unobservable
				Markets		Observable		Inputs
				for Identical		Inputs		(Level 3)
				Assets or		(Level 2)
				Liabilities
				(Level 1)
	June 30, 2014
	Assets
	Money market funds	$	54,814	$	54,814	$	—	$	—
	Short-term investments – commercial paper		998		—		998		—
	Short-term investments – corporate bonds		7,846		—		7,846		—
	Long-term investments – corporate bonds		1,004		—		1,004		—
	Total Assets	$	64,662	$	54,814	$	9,848	$	—
	December 31, 2013
	Assets
	Money market funds	$	25,201	$	25,201	$	—	$	—
	Short-term investments – commercial paper		1,997		—		1,997		—
	Short-term investments – corporate bonds		1,128		—		1,128		—
	Long-term investments – corporate bonds		6,189		—		6,189		—
	Total Assets	$	34,515	$	25,201	$	9,314	$	—

Investments_Tables

Investments (Tables)	6 Months Ended
	Jun. 30, 2014
Investments Debt And Equity Securities [Abstract]	'
Summary of Available-for-Sale Investments at Fair Value	'
	The Company’s available-for-sale investments at fair value consisted of the following at June 30, 2014 and December 31, 2013:
		June 30, 2014
		Cost		Gross			Gross		Estimated
				Unrealized			Unrealized		Fair Value
				(Losses)			Gains
		(In thousands)
	Commercial paper due in one year or less	$	998	$	—		$	—	$	998
	Corporate bonds due in one year or less		7,842		—			4		7,846
	Total short-term investments		8,840		—			4		8,844
	Total long-term investments		1,005		(1	)		—		1,004
	Total investments	$	9,845	$	(1	)	$	4	$	9,848
		December 31, 2013
		Cost		Gross			Gross		Estimated
				Unrealized			Unrealized		Fair Value
				(Losses)			Gains
		(In thousands)
	Commercial paper due in one year or less	$	1,997	$	—		$	—	$	1,997
	Corporate bonds due in one year or less		1,128		—			—		1,128
	Total short-term investments		3,125		—			—		3,125
	Corporate bonds due in one year or more		6,196		(7	)		—		6,189
	Total long-term investments		6,196		(7	)		—		6,189
	Total investments	$	9,321	$	(7	)	$	—	$	9,314

Property_and_Equipment_Tables

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2014
Property Plant And Equipment [Abstract]	'
Tabular Disclosure of Major Components of Property and Equipment and Related Accumulated Depreciation	'
	At June 30, 2014 and December 31, 2013, net property and equipment at cost consisted of the following:
	(In thousands)	June 30,		December 31,
		2014		2013
	Leasehold improvements	$	525	$	525
	Laboratory equipment and other		3,238		2,854
	Total property and equipment, at cost		3,763		3,379
	Less: accumulated depreciation		3,077		3,289
	Property and equipment, net	$	686	$	90

Comprehensive_Income_Loss_Tabl

Comprehensive Income (Loss) (Tables)	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Changes in Accumulated Balance of the Component of Other Comprehensive Gain (Loss)	'
	The following table includes the changes in the accumulated balance of the component of other comprehensive gain (loss) for the six months ended June 30, 2014:
	(In thousands)	Six Months
		ended June 30,
		2014
	Accumulated unrealized loss on available-for-sale securities at beginning of period	$	(7	)
	Change during the period		10
	Accumulated unrealized gain on available-for-sale securities at end of period	$	3

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Schedule of Assumptions Used to Determine Fair Value of Stock Options Granted During Period	'
	The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The following assumptions apply to the options to purchase 2,116,000 and 1,720,083 shares of common stock granted to employees and directors during the six months ended June 30, 2014 and 2013, respectively:
		Six Months Ended June 30,
		2014			2013
	Average risk free interest rate		1.6	%		0.9	%
	Expected dividend yield		—			—
	Expected lives (years)		4.8			5
	Expected volatility		83	%		61	%
	Weighted average grant date fair value of options granted during the period (per share)	$	2.61		$	0.36
	Weighted average exercise price of options granted during the period (per share)	$	4.01		$	0.69

Financing_Tables

Financing (Tables)	6 Months Ended
	Jun. 30, 2014
Text Block [Abstract]	'
May 2013 Follow-on Underwritten Public Offering	'
	On May 7, 2013, the Company closed a follow-on underwritten public offering, in which it sold 17,500,000 shares of common stock, together with matching warrants to purchase up to 17,500,000 shares of common stock, and pre-funded warrants to purchase up to 15,816,327 shares of common stock, together with matching warrants to purchase up to 15,816,327 shares of common stock, for aggregate gross proceeds of $16.5 million as follows:
		Combined Price		Common		Pre-funded		Matching
		to the Public		Stock		Warrants		Warrants
		(per share of
		common
		stock)
	Common stock and matching warrants sold (shares)	$	0.5		17,500,000		—		17,500,000
	Pre-funded warrants & matching warrants sold (shares)	$	0.49		—		15,816,327		15,816,327
	Total (shares)				17,500,000		15,816,327		33,316,327
	Warrant exercise price (per share)		—		—	$	0.01	$	0.47
	Term of warrant (years)		—		—		7		5

Organization_Additional_Inform

Organization - Additional Information (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'	'
Accumulated deficit	($430,153)	($412,884)

Cash_and_Cash_Equivalents_Addi

Cash and Cash Equivalents - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2014
Cash And Cash Equivalents [Abstract]	'
Maximum period to maturity to be considered a cash equivalent	'90 days

Fair_Value_of_Assets_and_Liabi2

Fair Value of Assets and Liabilities - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) (Fair value, measurements, recurring [Member], USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Total Assets	$64,662	$34,515
Money market funds [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Total Assets	54,814	25,201
Short-term investments - commercial paper [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Total Assets	998	1,997
Short-term investments - corporate bonds [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Total Assets	7,846	1,128
Long-term investments - corporate bonds [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Total Assets	1,004	6,189
Quoted prices in active markets for identical assets or liabilities (Level 1) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Total Assets	54,814	25,201
Quoted prices in active markets for identical assets or liabilities (Level 1) [Member] | Money market funds [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Total Assets	54,814	25,201
Significant other observable inputs (Level 2) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Total Assets	9,848	9,314
Significant other observable inputs (Level 2) [Member] | Short-term investments - commercial paper [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Total Assets	998	1,997
Significant other observable inputs (Level 2) [Member] | Short-term investments - corporate bonds [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Total Assets	7,846	1,128
Significant other observable inputs (Level 2) [Member] | Long-term investments - corporate bonds [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Total Assets	$1,004	$6,189

Investments_Summary_of_Availab

Investments - Summary of Available-for-Sale Investments at Fair Value (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost	$9,845	$9,321
Gross Unrealized (Losses)	-1	-7
Gross Unrealized Gains	4	'
Estimated Fair Value	9,848	9,314
Commercial paper due in one year or less [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost	998	1,997
Estimated Fair Value	998	1,997
Corporate bonds due in one year or less [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost	7,842	1,128
Gross Unrealized Gains	4	'
Estimated Fair Value	7,846	1,128
Total short-term investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost	8,840	3,125
Gross Unrealized Gains	4	'
Estimated Fair Value	8,844	3,125
Total long-term investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost	1,005	6,196
Gross Unrealized (Losses)	-1	-7
Estimated Fair Value	1,004	6,189
Corporate bonds due in one year or more [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost	'	6,196
Gross Unrealized (Losses)	'	-7
Estimated Fair Value	'	$6,189

Investments_Additional_Informa

Investments - Additional Information (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Investments Debt And Equity Securities [Abstract]	'	'
Realized gains or losses from available-for-sale securities	$0	$0
Auction Rate Securities, Noncurrent	0	0
Losses on investment	$0	$0

Property_and_Equipment_Tabular

Property and Equipment - Tabular Disclosure of Major Components of Property and Equipment and Related Accumulated Depreciation (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property Plant And Equipment [Abstract]	'	'
Leasehold improvements	$525	$525
Laboratory equipment and other	3,238	2,854
Total property and equipment, at cost	3,763	3,379
Less: accumulated depreciation	3,077	3,289
Property and equipment, net	$686	$90

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Property Plant And Equipment [Abstract]	'	'	'	'
Depreciation and amortization expense	$47	$33	$78	$75

Restricted_Cash_Additional_Inf

Restricted Cash - Additional Information (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Restricted Cash [Abstract]	'	'
Total restricted cash	$311,000	$311,000

Collaborations_Additional_Info

Collaborations - Additional Information (Detail) (Abbott Molecular [Member], USD $)	1 Months Ended
	Jun. 30, 2014	31-May-14	Apr. 30, 2014
Abbott Molecular [Member]	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Paid or expects to pay for external development expenses	$1,300,000	$6,700,000	'
Expected agreement term	'	'5 years	'
Maximum amount that may be credited towards any amount due from collaborator for third party license income received by the Company	'	'	$60,000,000
Percentage of third party license income received by the Company that is credited towards any amount due from collaborator	'	'	15.00%

Comprehensive_Income_Loss_Chan

Comprehensive Income (Loss) - Changes in Accumulated Balance of the Component of Other Comprehensive Gain (Loss) (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Comprehensive Income Net Of Tax [Abstract]	'	'
Accumulated unrealized gain or loss on available-for-sale securities, beginning of period	($7)	$0
Change during the period	10	'
Accumulated unrealized gain or loss on available-for-sale securities, end of period	$3	$0

Comprehensive_Income_Loss_Addi

Comprehensive Income (Loss) - Additional Information (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Comprehensive Income Net Of Tax [Abstract]	'	'	'
Accumulated unrealized gain or loss on available-for-sale securities	$3	($7)	$0

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Recorded charges in statement of operations	$785	$265	$1,320	$518
Options to purchase common stock granted to employees and directors	'	'	2,116,000	1,720,083
Employees [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock options vesting period	'	'	'4 years	'
Directors [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock options vesting period	'	'	'3 years	'

StockBased_Compensation_Schedu

Stock-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Stock Options Granted During Period (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'
Average risk free interest rate	1.60%	0.90%
Expected dividend yield	'	'
Expected lives (years)	'4 years 9 months 18 days	'5 years
Expected volatility	83.00%	61.00%
Weighted average grant date fair value of options granted during the period (per share)	$2.61	$0.36
Weighted average exercise price of options granted during the period (per share)	$4.01	$0.69

Net_Loss_per_Common_Share_Appl1

Net Loss per Common Share Applicable to Common Stockholders - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]	'	'	'	'
Total antidilutive securities	'	'	80,016,676	85,807,964
Preferred stock dividends	$118,000	$2,030,000	$303,000	$2,309,000
Series E preferred stock [Member]	'	'	'	'
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]	'	'	'	'
Preferred stock dividends	118,000	'	'	'
Series D and E Preferred Stock [Member]	'	'	'	'
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]	'	'	'	'
Preferred stock dividends	'	280,000	303,000	559,000
Loss on extinguishment of convertible preferred stock	'	$1,750,000	'	$1,750,000
Series D preferred stock [Member]	'	'	'	'
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]	'	'	'	'
Preferred stock conversion date	'	'	6-Feb-14	'

Common_Stock_Warrant_and_Optio1

Common Stock Warrant and Option Exercises and Employee Stock Purchases - Additional Information (Detail) (Common Stock Warrant And Option Exercises And Employee Stock Purchases [Member], USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Common Stock Warrant And Option Exercises And Employee Stock Purchases [Member]	'	'
Employee Stock Option And Warrant Exercises And ESPP Purchases [Line Items]	'	'
Number of shares of common stock issued for stock warrant and stock options exercised and ESPP purchases	3,364,033	3,574
Proceeds from stock issued for warrant and option exercises & ESPP purchases	$6,780,000	$2,000

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	6 Months Ended			0 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Feb. 06, 2014	Feb. 06, 2014	Jun. 30, 2014	Feb. 10, 2014	Dec. 31, 2013
				Series D preferred stock [Member]	Series D preferred stock [Member]	Series D preferred stock [Member]	Series D preferred stock [Member]
Schedule of Other Related Party Transactions [Line Items]	'	'	'	'	'	'	'
Preferred stock, shares issued	'	'	'	'	0	1,124,260	1,124,000
Preferred stock, shares outstanding	'	'	'	'	0	0	1,124,000
Shares of common stock issued upon conversion of Series D preferred stock	'	'	'	6,266,175	'	'	'
Number of shares of Series D Preferred Stock outstanding after conversion	'	'	0	'	'	'	'
Common stock issued in lieu of board fees	8,546	18,617	'	'	'	'	'
Common stock issued	$36,000	$9,000	'	'	'	'	'

Financing_Additional_Informati

Financing - Additional Information 1 (Detail) (USD $)	0 Months Ended
In Millions, except Share data, unless otherwise specified	Feb. 10, 2014	7-May-13	Feb. 10, 2014
Equity [Line Items]	'	'	'
Gross proceeds from sale of common stock and warrants excluding the proceeds from exercise of the warrants, if any	$40.10	$16.50	'
Sales price per share of prefunded warrants	'	'	$3.99
Estimated net proceeds from sale of common stock and warrants excluding the proceeds from exercise of the warrants, if any	$37.20	'	'
Common Stock [Member]	'	'	'
Equity [Line Items]	'	'	'
Common stock sold	7,867,438	'	'
Price to the public per share of common stock	$4	'	'
Pre-funded warrants [Member]	'	'	'
Equity [Line Items]	'	'	'
Shares of common stock that may be purchased upon exercise of the warrants	'	15,816,327	2,158,750
Warrants exercise price per share	'	0.01	0.01
Pre-funded warrants expiration date	10-Feb-21	'	'

Financing_Additional_Informati1

Financing - Additional Information 2 (Detail) (USD $)	0 Months Ended
In Millions, except Share data, unless otherwise specified	Feb. 10, 2014	7-May-13
Equity [Line Items]	'	'
Gross proceeds from sale of common stock and warrants excluding the proceeds from future exercise of the warrants, if any	$40.10	$16.50
Pre-funded warrants [Member]	'	'
Equity [Line Items]	'	'
Issuance of warrants to purchase shares common stock	'	15,816,327
Common Stock [Member]	'	'
Equity [Line Items]	'	'
Common stock sold	'	17,500,000
Matching Warrants [Member] | Pre-funded warrants [Member]	'	'
Equity [Line Items]	'	'
Issuance of warrants to purchase shares common stock	'	15,816,327
Matching Warrants [Member] | Common Stock [Member]	'	'
Equity [Line Items]	'	'
Issuance of warrants to purchase shares common stock	'	17,500,000

Financing_May_2013_Followon_Un

Financing - May 2013 Follow-on Underwritten Public Offering (Detail) (USD $)	0 Months Ended
	7-May-13	Feb. 10, 2014	7-May-13
Common Stock [Member]	'	'	'
Equity [Line Items]	'	'	'
Number of shares of common stock sold in financing	17,500,000	'	'
Common Stock and Matching Warrants Sold [Member]	'	'	'
Equity [Line Items]	'	'	'
Combined price to the public per share of common stock	$0.50	'	$0.50
Common Stock and Matching Warrants Sold [Member] | Common Stock [Member]	'	'	'
Equity [Line Items]	'	'	'
Number of shares of common stock sold in financing	17,500,000	'	'
Pre-funded Warrants & Matching Warrants Sold [Member]	'	'	'
Equity [Line Items]	'	'	'
Combined price to the public per share of common stock	$0.49	'	$0.49
Matching Warrants [Member]	'	'	'
Equity [Line Items]	'	'	'
Total (shares)	'	'	33,316,327
Warrant exercise price (per share)	'	'	0.47
Term of warrant (years)	'5 years	'	'
Matching Warrants [Member] | Common Stock and Matching Warrants Sold [Member]	'	'	'
Equity [Line Items]	'	'	'
Total (shares)	17,500,000	'	17,500,000
Matching Warrants [Member] | Pre-funded Warrants & Matching Warrants Sold [Member]	'	'	'
Equity [Line Items]	'	'	'
Total (shares)	15,816,327	'	15,816,327
Pre-funded warrants [Member]	'	'	'
Equity [Line Items]	'	'	'
Total (shares)	'	2,158,750	15,816,327
Warrant exercise price (per share)	'	0.01	0.01
Term of warrant (years)	'7 years	'	'
Pre-funded warrants [Member] | Pre-funded Warrants & Matching Warrants Sold [Member]	'	'	'
Equity [Line Items]	'	'	'
Total (shares)	15,816,327	'	15,816,327

Financing_Additional_Informati2

Financing - Additional Information 3 (Detail) (USD $)	0 Months Ended
In Millions, unless otherwise specified	7-May-13	7-May-13
Equity [Abstract]	'	'
Net proceeds from sale of common stock and warrants excluding the proceeds from future exercise of the warrants, if any	$14.50	'
Redemption price per share of warrants	0.01	'
Notice period to holder prior to redemption of warrants by Company	'30 days	'
Minimum trading days considered to redeem warrants	'20 days	'
Maximum trading days considered to redeem warrants	'30 days	'
Minimum closing price to redeem the warrants	'	2.8